AstraZeneca plc (NYSE:AZN) – Equities research analysts at Jefferies Group reduced their FY2018 earnings estimates for AstraZeneca in a research note issued on Monday, according to Zacks Investment Research. Jefferies Group analyst J. Holford now expects that the company will earn $1.72 per share for the year, down from their previous estimate of $1.78. Jefferies Group also issued estimates for AstraZeneca’s FY2019 earnings at $1.83 EPS and FY2022 earnings at $3.24 EPS.
AstraZeneca (NYSE:AZN) last announced its earnings results on Friday, February 2nd. The company reported $1.30 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.44 by $0.86. AstraZeneca had a net margin of 13.36% and a return on equity of 34.74%. The firm had revenue of $5.78 billion for the quarter, compared to analyst estimates of $5.49 billion. During the same quarter last year, the business earned $1.21 earnings per share. AstraZeneca’s revenue was up 3.4% compared to the same quarter last year.
Shares of AstraZeneca (NYSE AZN) opened at $33.82 on Tuesday. AstraZeneca has a 1 year low of $28.43 and a 1 year high of $36.70. The stock has a market cap of $85,738.52, a P/E ratio of 14.27, a P/E/G ratio of 2.02 and a beta of 0.71. The company has a debt-to-equity ratio of 0.93, a quick ratio of 0.62 and a current ratio of 0.80.
The firm also recently announced a semiannual dividend, which will be paid on Monday, March 19th. Stockholders of record on Friday, February 16th will be paid a $0.95 dividend. This represents a dividend yield of 5.62%. The ex-dividend date is Thursday, February 15th. AstraZeneca’s dividend payout ratio is presently 57.81%.
Hedge funds have recently modified their holdings of the company. Pinnacle Wealth Planning Services Inc. purchased a new position in shares of AstraZeneca in the 4th quarter valued at $101,000. Valeo Financial Advisors LLC purchased a new position in shares of AstraZeneca in the 3rd quarter valued at $133,000. Delpha Capital Management LLC purchased a new position in shares of AstraZeneca in the 4th quarter valued at $152,000. Calton & Associates Inc. purchased a new position in shares of AstraZeneca in the 4th quarter valued at $181,000. Finally, Wealthcare Advisory Partners LLC purchased a new position in shares of AstraZeneca in the 3rd quarter valued at $184,000. 15.15% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “AstraZeneca plc to Post FY2018 Earnings of $1.72 Per Share, Jefferies Group Forecasts (AZN)” was originally reported by Week Herald and is owned by of Week Herald. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://weekherald.com/2018/03/14/fy2018-earnings-estimate-for-astrazeneca-plc-issued-by-jefferies-group-azn.html.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.